191 related articles for article (PubMed ID: 30928532)
21. Complications and continuation rates associated with 2 types of long-acting contraception.
Berenson AB; Tan A; Hirth JM
Am J Obstet Gynecol; 2015 Jun; 212(6):761.e1-8. PubMed ID: 25555662
[TBL] [Abstract][Full Text] [Related]
22. The effect of rifampin on serum etonogestrel concentrations and biomarkers of ovulation among contraceptive implant users: A pharmacokinetic and pharmacodynamic study.
Lazorwitz A; Sheeder J; Teal S
Contraception; 2023 Jul; 123():110035. PubMed ID: 36997081
[TBL] [Abstract][Full Text] [Related]
23. Prolonged use of the etonogestrel implant and levonorgestrel intrauterine device: 2 years beyond Food and Drug Administration-approved duration.
McNicholas C; Swor E; Wan L; Peipert JF
Am J Obstet Gynecol; 2017 Jun; 216(6):586.e1-586.e6. PubMed ID: 28147241
[TBL] [Abstract][Full Text] [Related]
24. Effectiveness and continuation rates of the etonogestrel-subdermal contraceptive implant versus short-acting contraceptive methods offered at no cost in Campinas, Brazil.
Laporte M; Marcelino AC; da Cunha Pereira P; Espejo-Arce X; Juliato CT; Bahamondes L
Int J Gynaecol Obstet; 2024 Jul; 166(1):305-311. PubMed ID: 38328989
[TBL] [Abstract][Full Text] [Related]
25. Safety and efficacy of Implanon, a single-rod implantable contraceptive containing etonogestrel.
Funk S; Miller MM; Mishell DR; Archer DF; Poindexter A; Schmidt J; Zampaglione E;
Contraception; 2005 May; 71(5):319-26. PubMed ID: 15854630
[TBL] [Abstract][Full Text] [Related]
26. Pilot study of a novel, alternative subdermal scapular insertion site for the etonogestrel contraceptive implant.
Clure C; Sheeder J; Lazorwitz A
Contraception; 2024 Jul; 135():110442. PubMed ID: 38552822
[TBL] [Abstract][Full Text] [Related]
27. An exploratory study on the possible association of serum etonogestrel concentrations with mood concerns and symptoms among contraceptive implant users.
Diamond B; Sheeder J; Lazorwitz A
Contraception; 2024 Jan; 129():110298. PubMed ID: 37802462
[TBL] [Abstract][Full Text] [Related]
28. Tamoxifen for the treatment of breakthrough bleeding with the etonogestrel implant: a randomized controlled trial.
Simmons KB; Edelman AB; Fu R; Jensen JT
Contraception; 2017 Feb; 95(2):198-204. PubMed ID: 27725164
[TBL] [Abstract][Full Text] [Related]
29. Safety, efficacy and acceptability of implanon a single rod implantable contraceptive (etonogestrel) in University of Benin Teaching Hospital.
Aisien AO; Enosolease ME
Niger J Clin Pract; 2010 Sep; 13(3):331-5. PubMed ID: 20857796
[TBL] [Abstract][Full Text] [Related]
30. Influence of age on tolerability, safety and effectiveness of subdermal contraceptive implants.
López Del Cerro E; Serrano Diana C; Castillo Cañadas AM; González Mirasol E; García Santos F; Gómez García MT; González de Merlo G
J Obstet Gynaecol; 2018 Oct; 38(7):979-984. PubMed ID: 29553853
[TBL] [Abstract][Full Text] [Related]
31. Tamoxifen for the Treatment of Etonogestrel Implant-Associated Bleeding in an Adolescent Gynecology Practice.
Friedman JC; Buyers E; Laurin J; Hampanda K; Alaniz VI
J Pediatr Adolesc Gynecol; 2022 Jun; 35(3):341-345. PubMed ID: 34780932
[TBL] [Abstract][Full Text] [Related]
32. Etonogestrel-releasing contraceptive implant in a patient using thalidomide for the treatment of erythema nodosum leprosum: a case report.
Ferreira-Filho ES; Bahamondes L; Duarte DC; Guimarães ALM; de Almeida PG; Soares-Júnior JM; Baracat EC; Sorpreso ICE
Gynecol Endocrinol; 2022 Jan; 38(1):90-93. PubMed ID: 34486922
[TBL] [Abstract][Full Text] [Related]
33. Immediate versus delayed insertion of an etonogestrel releasing implant at medical abortion-a randomized controlled equivalence trial.
Hognert H; Kopp Kallner H; Cameron S; Nyrelli C; Jawad I; Heller R; Aronsson A; Lindh I; Benson L; Gemzell-Danielsson K
Hum Reprod; 2016 Nov; 31(11):2484-2490. PubMed ID: 27664217
[TBL] [Abstract][Full Text] [Related]
34. Etonogestrel implant use in women primarily choosing a combined oral contraceptive pill: A proof-of-concept trial.
Chen MJ; Hsia JK; Creinin MD
Contraception; 2018 Jun; 97(6):533-537. PubMed ID: 29496473
[TBL] [Abstract][Full Text] [Related]
35. Weight change in adolescents who used hormonal contraception.
Risser WL; Gefter LR; Barratt MS; Risser JM
J Adolesc Health; 1999 Jun; 24(6):433-6. PubMed ID: 10401972
[TBL] [Abstract][Full Text] [Related]
36. One-year follow-up of immediate postpartum contraceptive implant insertion in adolescents.
Barbieri MM; Dantas-Silva A; Caleffi LS; Morais SS; Juliato CRT; Bahamondes L; Surita FG
Eur J Contracept Reprod Health Care; 2023 Feb; 28(1):58-64. PubMed ID: 36287505
[TBL] [Abstract][Full Text] [Related]
37. Bleeding profile in users of an etonogestrel sub-dermal implant: effects of anthropometric variables. An observational uncontrolled preliminary study in Italian population.
Di Carlo C; Guida M; De Rosa N; Sansone A; Gargano V; Cagnacci A; Nappi C
Gynecol Endocrinol; 2015 Jun; 31(6):491-4. PubMed ID: 26213863
[TBL] [Abstract][Full Text] [Related]
38. Combined oral contraceptive treatment for bleeding complaints with the etonogestrel contraceptive implant: a randomised controlled trial.
Hou MY; McNicholas C; Creinin MD
Eur J Contracept Reprod Health Care; 2016 Oct; 21(5):361-6. PubMed ID: 27419258
[TBL] [Abstract][Full Text] [Related]
39. Bioequivalence and x-ray visibility of a radiopaque etonogestrel implant versus a non-radiopaque implant: a 3-year, randomized, double-blind study.
Schnabel P; Merki-Feld GS; Malvy A; Duijkers I; Mommers E; van den Heuvel MW
Clin Drug Investig; 2012 Jun; 32(6):413-22. PubMed ID: 22540269
[TBL] [Abstract][Full Text] [Related]
40. Gene expression associated with unfavorable vaginal bleeding in women using the etonogestrel subdermal contraceptive implant: a prospective study.
Torelli FR; Rodrigues-Peres RM; Monteiro I; Lopes-Cendes I; Bahamondes L; Juliato CRT
Sci Rep; 2024 May; 14(1):11062. PubMed ID: 38745005
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
